Your session is about to expire
← Back to Search
Procedure
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
Phase 2
Waitlist Available
Led By Steven A Libutti, MD
Research Sponsored by National Institutes of Health Clinical Center (CC)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 weeks, 3 months, and 6 months following treatment
Awards & highlights
No Placebo-Only Group
Summary
RATIONALE: Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have unresectable primary or metastatic liver cancer.
Eligible Conditions
- Hepatocellular Carcinoma
- Cancer
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 6 weeks, 3 months, and 6 months following treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 weeks, 3 months, and 6 months following treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Compare Fludeoxyglucose (18F) Positron-Emission Tomography (FDG-PET) Results With Biopsies
Compare Fludeoxyglucose (18F) Positron-Emission Tomography (FDG-PET) Results With Computed Tomography (CT)
Compare Fludeoxyglucose (18F) Positron-Emission Tomography (FDG-PET) Results With Serum Markers
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Radiofrequency ablation in liver cancerExperimental Treatment8 Interventions
This trial is designed to gain experience with the use of ablation devices with liver tumors. Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
radiofrequency ablation
2016
Completed Phase 2
~4950
computed tomography
2010
Completed Phase 2
~1200
positron emission tomography
2010
Completed Phase 2
~1370
magnetic resonance imaging
2002
Completed Phase 2
~1820
gadopentetate dimeglumine
2002
Completed Phase 2
~720
radionuclide imaging
2006
Completed Phase 1
~1120
ultrasound imaging
2002
Completed Phase 2
~1330
Find a Location
Who is running the clinical trial?
National Institutes of Health Clinical Center (CC)Lead Sponsor
389 Previous Clinical Trials
30,879,692 Total Patients Enrolled
2 Trials studying Hepatocellular Carcinoma
80 Patients Enrolled for Hepatocellular Carcinoma
National Cancer Institute (NCI)NIH
13,956 Previous Clinical Trials
41,112,399 Total Patients Enrolled
43 Trials studying Hepatocellular Carcinoma
5,687 Patients Enrolled for Hepatocellular Carcinoma
Steven A Libutti, MDPrincipal InvestigatorNational Cancer Institute, National Institutes of Health